Breaking News

Catalent, Adamas Enter CTM Agreement

Catalent to manufacture ADS-5102 for Phase III trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions and Adamas Pharmaceuticals have entered an agreement for the manufacture of ADS-5102 (amantadine HCl) extended release capsules for Phase III trials. ADS-5102 is an investigational drug being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.   “We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials,” said Gregory T. Went, Ph.D., Adamas chairman and chief executive officer.   ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters